Rev Esp Quimioter 2021;34(Suppl.1):22-25

Tedizolid: new data and experiences for clinical practice

MIGUEL SALAVERT LLETÍ, VÍCTOR GARCÍA-BUSTOS, LAURA MORATA RUIZ, MARTA DAFNE CABAÑERO-NAVALON

Published: 30 September 2021

http://www.doi.org/10.37201/req/s01.06.2021

The most relevant information on the clinical uses of tedizolid from studies published in the last 18 months is presented in this brief review. The most important data indicate better tolerance and safety profile of long-term therapeutic regimes in off-label indications, such as osteoarticular infections and those caused by mycobacteria. Its lower risk of hazardous interactions compared to linezolid should be emphasized. Furthermore, tedizolid in its combination with rifampicin shows a more favourable way of acting as demonstrated in vitro and in vivo studies. A recent trial also opens the door for its potential use in nosocomial pneumonia caused by Gram-positive bacteria.

Rev Esp Quimioter 2021; 34(Suppl. 1):22-25 [Full-text PDF]